Jaime Bosch
#87,320
Most Influential Person Now
Researcher ORCID ID = 0000-0003-3414-0055
Jaime Bosch's AcademicInfluence.com Rankings
Jaime Boschcomputer-science Degrees
Computer Science
#2945
World Rank
#3084
Historical Rank
Machine Learning
#246
World Rank
#249
Historical Rank
Artificial Intelligence
#414
World Rank
#421
Historical Rank
Database
#514
World Rank
#538
Historical Rank
Download Badge
Computer Science
Jaime Bosch's Degrees
- PhD Computer Science University of Barcelona
- Masters Computer Science University of Barcelona
- Bachelors Computer Science University of Barcelona
Similar Degrees You Can Earn
Why Is Jaime Bosch Influential?
(Suggest an Edit or Addition)Jaime Bosch's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases (2017) (1346)
- The treatment of portal hypertension: A meta‐analytic review (1995) (1063)
- Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. (2005) (881)
- Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. (2007) (865)
- Early use of TIPS in patients with cirrhosis and variceal bleeding. (2010) (844)
- Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. (1996) (835)
- Pharmacological treatment of portal hypertension: an evidence-based approach. (1999) (772)
- Management of varices and variceal hemorrhage in cirrhosis. (2010) (676)
- Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis (1995) (590)
- Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. (1990) (577)
- The clinical use of HVPG measurements in chronic liver disease (2009) (528)
- Angiogenesis in liver disease. (2009) (523)
- Hemodynamic response to pharmacological treatment of portal hypertension and long‐term prognosis of cirrhosis (2003) (513)
- Pathophysiology of portal hypertension. (1992) (500)
- Complications of cirrhosis. I. Portal hypertension. (2000) (486)
- Angiotensin II induces contraction and proliferation of human hepatic stellate cells. (2000) (464)
- Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. (2006) (463)
- Prognostic value of early measurements of portal pressure in acute variceal bleeding. (1999) (460)
- Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. (2004) (452)
- Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation (2006) (428)
- Portal hypertension and variceal bleeding: An AASLD single topic symposium (1998) (421)
- Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. (1998) (419)
- Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. (2013) (419)
- Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. (2004) (404)
- Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: Effects on renal function and vasoactive systems (1998) (378)
- Baveno VII - Renewing consensus in portal hypertension. (2021) (363)
- Current management of portal hypertension. (2003) (354)
- Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. (2007) (345)
- Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. (2009) (328)
- Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. (2009) (316)
- The management of portal hypertension: rational basis, available treatments and future options. (2008) (311)
- Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. (2012) (309)
- Non invasive evaluation of portal hypertension using transient elastography. (2012) (307)
- TIPS for Budd-Chiari syndrome: long-term results and prognostics factors in 124 patients. (2008) (301)
- Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: A randomized, controlled trial (2008) (301)
- Definitions, methodology and therapeutic strategies in portal hypertension. A Consensus Development Workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990. (1992) (298)
- Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. (2008) (294)
- Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation (2006) (292)
- Effects of Propranolol on Azygos Venous Blood Flow and Hepatic and Systemic Hemodynamics in Cirrhosis (1984) (291)
- Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C (2008) (291)
- Portal hypertension and its complications. (2008) (285)
- Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats (2009) (285)
- Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. (2003) (282)
- Early use of TIPS in patients with cirrhosis and variceal bleeding (2010) (273)
- Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long‐term results of a randomized multicentre study (2007) (270)
- Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition. (1992) (266)
- Gastric mucosal vascular ectasias causing bleeding in cirrhosis. A distinct entity associated with hypergastrinemia and low serum levels of pepsinogen I. (1987) (264)
- Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis (1991) (263)
- Renal failure after upper gastrointestinal bleeding in cirrhosis: Incidence, clinical course, predictive factors, and short‐term prognosis (2001) (261)
- Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: Comparison with vasopressin (1981) (257)
- Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. (2004) (255)
- Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis (2002) (254)
- Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. (1991) (252)
- Prevention of variceal rebleeding (2003) (249)
- Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. (2004) (248)
- Portal hypertension and variceal bleeding—Unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single‐topic conference (2008) (244)
- Assessing portal hypertension in liver diseases (2013) (243)
- Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: A systematic review and meta‐analysis (2015) (242)
- Effects of inhibiting nitric oxide biosynthesis on the systemic and splanchnic circulation of rats with portal hypertension (1992) (242)
- A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. (2014) (240)
- Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis (2011) (240)
- Pharmacological Reduction of Portal Pressure and Long-Term Risk of First Variceal Bleeding in Patients with Cirrhosis (2006) (238)
- Hyperintense globus pallidus on T1‐weighted MRI in cirrhotic patients is associated with severity of liver failure (1993) (226)
- An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis (2007) (226)
- Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension (1982) (226)
- Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. (2016) (223)
- Functional aspects on the pathophysiology of portal hypertension in cirrhosis. (2012) (219)
- TIPS versus drug therapy in preventing variceal rebleeding in advanced cirrhosis: A randomized controlled trial (2002) (219)
- A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis (2005) (216)
- Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis (2011) (213)
- Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. (2005) (212)
- Incidence, prevalence, and clinical significance of abnormal hematologic indices in compensated cirrhosis. (2009) (212)
- Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. (2018) (208)
- Comparison of Intravenous Somatostatin and Vasopressin Infusions in Treatment of Acute Variceal Hemorrhage (1984) (208)
- Wedged hepatic venous pressure adequately reflects portal pressure in hepatitis C virus–related cirrhosis (1999) (207)
- TIPS is a useful long‐term derivative therapy for patients with Budd‐Chiari syndrome uncontrolled by medical therapy (2002) (207)
- Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease (2017) (205)
- Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. (2009) (204)
- Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The “Anticipate” study (2016) (204)
- β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial (2019) (203)
- Simvastatin treatment improves liver sinusoidal endothelial dysfunction in CCl4 cirrhotic rats. (2007) (203)
- Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis. (2017) (202)
- Sinusoidal Endothelial Dysfunction Precedes Inflammation and Fibrosis in a Model of NAFLD (2012) (202)
- Randomized comparison of long‐term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis (2002) (201)
- Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis (2010) (199)
- Measurement of Azygos Venous Blood Flow by a Continuous Thermal Dilution Technique: An Index of Blood Flow Through Gastroesophageal Collaterals in Cirrhosis (1984) (199)
- Multicenter Randomized Controlled Trial of Terlipressin Versus Sclerotherapy in the Treatment of Acute Variceal Bleeding: The TEST Study (2000) (197)
- Real-time shear-wave elastography: applicability, reliability and accuracy for clinically significant portal hypertension. (2015) (196)
- Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension. (2010) (191)
- Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial (1991) (190)
- Measurement of portal pressure and its role in the management of chronic liver disease. (2006) (189)
- Endoscopic measurement of variceal pressure in cirrhosis: correlation with portal pressure and variceal hemorrhage. (1989) (187)
- Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. (2001) (185)
- Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study (2017) (182)
- Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis (1993) (182)
- Portal Hypertension in Children: Expert Pediatric Opinion on the Report of the Baveno V Consensus Workshop on Methodology of Diagnosis and Therapy in Portal Hypertension (2012) (181)
- Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments. (2015) (177)
- Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. (2012) (177)
- Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension (2000) (176)
- Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet‐derived growth factor blockade in rats (2007) (175)
- Measurement of azygos venous blood flow in the evaluation of portal hypertension in patients with cirrhosis. Clinical and haemodynamic correlations in 100 patients. (1985) (174)
- Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial (2016) (173)
- Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis (1980) (173)
- Portal hypertension-related complications after acute portal vein thrombosis: impact of early anticoagulation. (2008) (172)
- The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. (2013) (170)
- Enhancement of portal pressure reduction by the association of isosorbide‐5‐mononitrate to propranolol administration in patients with cirrhosis (1990) (163)
- Portal hypertension and gastrointestinal bleeding. (2008) (160)
- Carvedilol, a new nonselective beta‐blocker with intrinsic anti‐alpha1‐adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis (1999) (159)
- Propranolol plus placebo versus propranolol plus isosorbide‐5‐mononitrate in the prevention of a first variceal bleed: A double‐blind RCT (2003) (158)
- Noninvasive Prediction of Clinically Significant Portal Hypertension and Esophageal Varices in Patients With Compensated Liver Cirrhosis (2008) (156)
- KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins (2014) (151)
- Hemodynamic evaluation of the patient with portal hypertension. (1986) (151)
- Endoscopic band ligation in the treatment of portal hypertension (2005) (151)
- Atrial natriuretic factor in cirrhosis with ascites: Plasma levels, cardiac release and splanchnic extraction (1988) (150)
- The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials (2019) (150)
- Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis. Effects on splanchnic and systemic hemodynamics and liver function. (1989) (149)
- Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Variceal Bleeding Study Group. (1996) (149)
- Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension (2011) (146)
- Effect of angiotensin‐ll blockade on systemic and hepatic haemodynamics and on the renin‐angiotensin‐aldosterone system in cirrhosis with ascites (1981) (146)
- Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding. (2001) (145)
- PTFE‐covered stents improve TIPS patency in Budd‐Chiari syndrome (2004) (145)
- Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. (2004) (142)
- Effects of blood volume restitution following a portal hypertensive–related bleeding in anesthetized cirrhotic rats (2001) (142)
- Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis☆☆☆ (2001) (139)
- Evidence against a role for inducible nitric oxide synthase in the hyperdynamic circulation of portal-hypertensive rats. (1995) (138)
- Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: A double‐blind hemodynamic investigation (1995) (137)
- Cyclooxygenase‐derived products modulate the increased intrahepatic resistance of cirrhotic rat livers (2003) (137)
- Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension. (1996) (136)
- Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive beta-blockers. (2001) (135)
- Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. (2012) (135)
- Gastric endoscopic features in portal hypertension: final report of a consensus conference, Milan, Italy, September 19, 1992. (1994) (134)
- Vascular deterioration in cirrhosis: the big picture. (2007) (134)
- Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis (2007) (132)
- Increased oxidative stress in cirrhotic rat livers: A potential mechanism contributing to reduced nitric oxide bioavailability (2007) (127)
- Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. (1985) (126)
- Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function. (1995) (126)
- Hemodynamic effects of acute changes in intra-abdominal pressure in patients with cirrhosis. (1993) (125)
- Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury. (2019) (125)
- Development of hyperdynamic circulation and response to β‐blockers in compensated cirrhosis with portal hypertension (2016) (124)
- Effects of low‐sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis (1994) (123)
- Propranolol for the prevention of first esophageal variceal hemorrhage: A lifetime commitment? (2001) (123)
- New therapeutic paradigm for patients with cirrhosis (2012) (122)
- Gas exchange and pulmonary vascular reactivity in patients with liver cirrhosis. (1987) (121)
- Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. (2007) (119)
- Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? (2002) (119)
- Effect of Meal Ingestion on Liver Stiffness in Patients with Cirrhosis and Portal Hypertension (2013) (118)
- Effects of ethanol consumption on hepatic hemodynamics in patients with alcoholic cirrhosis. (1997) (118)
- Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy (2006) (115)
- Prognostic value of acute hemodynamic response to i.v. propranolol in patients with cirrhosis and portal hypertension. (2009) (115)
- Idiopathic portal hypertension: Natural history and long‐term outcome (2014) (114)
- Preemptive‐TIPS Improves Outcome in High‐Risk Variceal Bleeding: An Observational Study (2018) (113)
- Transjugular liver biopsy in BMT. (1993) (112)
- Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension (2006) (112)
- The lung in patients with cirrhosis. (1990) (111)
- Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: comparison with vasopressin. (1981) (111)
- The eNOS cofactor tetrahydrobiopterin improves endothelial dysfunction in livers of rats with CCl4 cirrhosis (2006) (110)
- Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats. (2013) (110)
- Noninvasive measurement of the pressure of esophageal varices using an endoscopic gauge: Comparison with measurements by variceal puncture in patients undergoing endoscopic sclerotherapy (1986) (109)
- Increased gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. (1992) (109)
- Time profile of the haemodynamic effects of terlipressin in portal hypertension. (1997) (108)
- Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension (2017) (108)
- Renin, aldosterone and renal haemodynamics in cirrhosis with ascites (1979) (108)
- Impact of anticoagulation on upper‐gastrointestinal bleeding in cirrhosis. A retrospective multicenter study (2015) (107)
- Association of transdermal nitroglycerin to vasopressin infusion in the treatment of variceal hemorrhage: A placebo‐controlled clinical trial (1989) (107)
- Primary prophylaxis of variceal bleeding in children and the role of MesoRex Bypass: Summary of the Baveno VI Pediatric Satellite Symposium (2016) (106)
- Extrahepatic portal vein thrombosis. (2008) (106)
- Enhanced vasoconstrictor prostanoid production by sinusoidal endothelial cells increases portal perfusion pressure in cirrhotic rat livers. (2007) (106)
- Role of hepatic vein catheterisation and transient elastography in the diagnosis of idiopathic portal hypertension. (2012) (105)
- Steady-state extrarenal sorbitol clearance as a measure of hepatic plasma flow. (1988) (104)
- Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. (2010) (104)
- Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. (2010) (104)
- Plasma renin activity and urinary sodium excretion as prognostic indicators in nonazotemic cirrhosis with ascites. (1981) (103)
- Nadolol plus isosorbide mononitrate alone or associated with band ligation in the prevention of recurrent bleeding: a multicentre randomised controlled trial (2009) (102)
- Randomized controlled trial of sclerotherapy versus somatostatin infusion in the prevention of early rebleeding following acute variceal hemorrhage in patients with cirrhosis (1998) (101)
- 5-lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. (2002) (100)
- Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. (1998) (100)
- Chronic Bile Duct Ligation in the Dog: Hemodynamic Characterization of a Portal Hypertensive Model (2007) (99)
- Acute and chronic cyclooxygenase blockage in portal-hypertensive rats: influence in nitric oxide biosynthesis. (1996) (98)
- Randomized comparison of long-term losartan versus propranolol in lowering portal pressure in cirrhosis. (2001) (98)
- Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. (1991) (98)
- Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: Influence of the extent of portal‐systemic shunting (1989) (98)
- Addition of simvastatin to cold storage solution prevents endothelial dysfunction in explanted rat livers (2012) (97)
- Functional renal failure and haemorrhagic gastritis associated with endotoxaemia in cirrhosis. (1977) (97)
- Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension. (2010) (96)
- Portal hypertension in primary biliary cirrhosis. Relationship with histological features. (1987) (96)
- Influence of pharmacological agents on portal hemodynamics: basis for its use in the treatment of portal hypertension. (1999) (96)
- Budd-Chiari Syndrome Secondary to Antiphospholipid Syndrome: Clinical and Immunologic Characteristics of 43 Patients (2001) (96)
- The treatment of acute variceal bleeding. (2007) (95)
- Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats. (1988) (94)
- Increased adrenomedullin levels in cirrhosis: relationship with hemodynamic abnormalities and vasoconstrictor systems. (1998) (93)
- Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension (2010) (93)
- Gene Expression of Endothelin-1 and ETA and ETB Receptors in Human Cirrhosis: Relationship with Hepatic Hemodynamics (1998) (92)
- Long-term haemodynamic effects of isosorbide 5-mononitrate in patients with cirrhosis and portal hypertension. (1990) (91)
- Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. (1980) (89)
- Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. (2016) (89)
- The role of portal pressure in the severity of bleeding in portal hypertensive rats (2000) (89)
- Renal failure after upper gastrointestinal bleeding in cirrhosis. Incidence, clinical course, predictive factors and short-term prognosis (2001) (88)
- Favorable effects of total paracentesis on splanchnic hemodynamics in cirrhotic patients with tense ascites (1994) (88)
- Idiopathic Portal Hypertension in Patients With HIV Infection Treated With Highly Active Antiretroviral Therapy (2009) (88)
- Reduction of variceal pressure by propranolol: Comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis (1993) (87)
- Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis (2003) (87)
- Decreased systemic vascular sensitivity to norepinephrine in portal hypertensive rats: role of hyperglucagonism. (1990) (87)
- Glucagon hinders the effects of somatostatin on portal hypertension. A study in rats with partial portal vein ligation. (1991) (87)
- Effects of simvastatin administration on rodents with lipopolysaccharide‐induced liver microvascular dysfunction (2013) (87)
- Randomized Placebo-Controlled Trial of Emricasan in Non-alcoholic Steatohepatitis (NASH) Cirrhosis with Severe Portal Hypertension. (2019) (87)
- Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS. (2011) (86)
- Somatostatin and analogues in portal hypertension (2002) (86)
- Non-Invasive Diagnostic and Prognostic Evaluation of Liver Cirrhosis and Portal Hypertension (2011) (85)
- Portal cholangiopathy: radiological classification and natural history (2011) (83)
- How to prevent varices from bleeding: shades of grey--the case for nonselective beta blockers. (2007) (82)
- Heme oxygenase attenuates oxidative stress and inflammation, and increases VEGF expression in portal hypertensive rats. (2006) (82)
- Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis (1995) (81)
- Renal effects of acute isosorbide‐5‐mononitrate administration in cirrhosis (1993) (80)
- Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension. (2018) (80)
- Portal Hypertension Collaborative Group. Beta-blockers to prevent gastroesophageal varices in patient with cirrhosis. (2005) (80)
- Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension (1988) (80)
- Ascites after liver transplantation (2000) (79)
- Circadian variations of portal pressure and variceal hemorrhage in patients with cirrhosis (1994) (79)
- Carvedilol for portal hypertension in patients with cirrhosis (2010) (78)
- Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. (2019) (78)
- Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. (2020) (78)
- Cyclooxygenase-1 inhibition corrects endothelial dysfunction in cirrhotic rat livers. (2003) (76)
- Current concepts on the pathophysiology of portal hypertension. (2007) (76)
- Effects of aging on liver microcirculatory function and sinusoidal phenotype (2018) (75)
- Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. (2020) (75)
- Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension (2008) (75)
- Beneficial effects of intravenous albumin infusion on the hemodynamic and humoral changes after total paracentesis. (1995) (73)
- Effects of alpha-adrenergic stimulation and beta-adrenergic blockade on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis. (1987) (73)
- Alcohol‐induced bone disease in the absence of severe chronic liver damage (1994) (73)
- Endoscopic assessment of variceal volume and wall tension in cirrhotic patients: effects of pharmacological therapy. (1997) (72)
- Apelin signaling modulates splanchnic angiogenesis and portosystemic collateral vessel formation in rats with portal hypertension. (2009) (72)
- PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. (2012) (72)
- The portal hypertension syndrome: etiology, classification, relevance, and animal models (2018) (71)
- Hemodynamic effects of α‐adrenergic blockade with prazosin in cirrhotic patients with portal hypertension (1994) (71)
- Review article: the modern management of portal hypertension – primary and secondary prophylaxis of variceal bleeding in cirrhotic patients (2008) (71)
- Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: A clinical‐hemodynamic correlation study (2010) (71)
- Insulin resistance and liver microcirculation in a rat model of early NAFLD. (2011) (70)
- Renal failure associated with demeclocycline in cirrhosis. (1977) (70)
- On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease (1993) (70)
- Effect of transjugular intrahepatic portosystemic shunt on pulmonary gas exchange in patients with portal hypertension and hepatopulmonary syndrome. (2005) (70)
- Sinusoidal endothelial COX-1-derived prostanoids modulate the hepatic vascular tone of cirrhotic rat livers. (2005) (70)
- Pulmonary hemodynamics and gas exchange during exercise in liver cirrhosis. (1989) (69)
- Effects of vasopressin on the intravariceal pressure in patients with cirrhosis: Comparison with the effects on portal pressure (1988) (69)
- Hemodynamic effects of glucagon in portal hypertension (1990) (68)
- Cross-talk between autophagy and KLF2 determines endothelial cell phenotype and microvascular function in acute liver injury. (2017) (67)
- Varices and Variceal Hemorrhage in Cirrhosis: A New View of an Old Problem. (2015) (66)
- The portal pressure response to beta-blockade is greater in cirrhotic patients without varices than in those with varices. (1997) (65)
- Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta‐analysis (2017) (65)
- The value of Doppler US in the study of hepatic hemodynamics. Consensus conference (Bologna, Italy, 12 September, 1989). (1990) (65)
- Propranolol decreases portal pressure without changing portocollateral resistance in cirrhotic rats (1989) (65)
- Double‐blind investigation of the effects of propranolol and placebo on the pressure of esophageal varices in patients with portal hypertension (1991) (65)
- Effects of F‐180, a new selective vasoconstrictor peptide, compared with terlipressin and vasopressin on systemic and splanchnic hemodynamics in a rat model of portal hypertension (1998) (64)
- Effects of propranolol on the hepatic hemodynamic response to physical exercise in patients with cirrhosis (1998) (64)
- Liver sinusoidal endothelial dysfunction after LPS administration: a role for inducible-nitric oxide synthase. (2014) (64)
- Acute and long‐term effects of inhaled iloprost in portopulmonary hypertension (2010) (63)
- Natural history and management of esophagogastric varices in chronic noncirrhotic, nontumoral portal vein thrombosis (2016) (63)
- Prevalence of the Cys282Tyr and His63Asp HFE gene mutations in Spanish patients with hereditary hemochromatosis and in controls. (1998) (63)
- Autoimmune hepatitis triggered by SARS-CoV-2 vaccination (2021) (62)
- Simvastatin maintains function and viability of steatotic rat livers procured for transplantation. (2013) (62)
- Propranolol versus sclerotherapy in preventing variceal rebleeding: a randomized controlled trial. (1993) (61)
- Increased hepatic resistance: a new target in the pharmacologic therapy of portal hypertension. (2005) (61)
- Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin. (2008) (61)
- Association Between Severe Portal Hypertension and Risk of Liver Decompensation in Patients With Hepatitis C, Regardless of Response to Antiviral Therapy. (2015) (60)
- Beta-blockers in cirrhosis: Evidence-based indications and limitations (2019) (60)
- Cirrhosis as new indication for statins (2020) (60)
- Sequential Functions of CPEB1 and CPEB4 Regulate Pathologic Expression of Vascular Endothelial Growth Factor and Angiogenesis in Chronic Liver Disease. (2016) (60)
- Propranolol plus isosorbide‐5‐mononitrate for portal hypertension in cirrhosis: Long‐term hemodynamic and renal effects (1994) (60)
- Increasing intra‐abdominal pressure increases pressure, volume, and wall tension in esophageal varices (2002) (60)
- Pathophysiology of decompensated cirrhosis: Portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction. (2021) (60)
- Emricasan (IDN‐6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension (2018) (60)
- Existence of a platelet-adhesion defect in patients with cirrhosis independent of hematocrit: studies under flow conditions. (1996) (59)
- Effect of bolus injection and continuous infusion of somatostatin on gastric perfusion in cirrhotic patients with portal‐hypertensive gastropathy (1994) (59)
- Prevalence of the Cys282Tyr and His63Asp HFE gene mutations in Spanish patients with hereditary hemochromatosis and in controls (1998) (59)
- Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats. (2013) (59)
- NAD(P)H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats (2006) (59)
- The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells (2017) (59)
- The role of vasoactive mediators in portal hypertension. (1995) (58)
- Involvement of nitric oxide and prostaglandins in gastric mucosal hyperemia of portal‐hypertensive anesthetized rats (1993) (57)
- 103 Multicenter randomized placebo-controlled trial of non-selective beta-blockers in the prevention of the complications of portal hypertension: final results and identification of a predictive factor (2003) (57)
- Effects of propranolol on gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy (1993) (57)
- Clinical types and drug therapy of renal impairment in cirrhosis (1975) (56)
- Prevention and treatment of variceal haemorrhage in 2017 (2017) (56)
- Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. (2020) (56)
- Sonography of the caudate vein: value in diagnosing Budd-Chiari syndrome. (2003) (55)
- Measurement of variceal pressure with an endoscopic pressure sensitive gauge: validation and effect of propranolol therapy in chronic conditions. (1996) (55)
- Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. (2020) (54)
- Impact of deep sedation on the accuracy of hepatic and portal venous pressure measurements in patients with cirrhosis (2014) (53)
- Effect of pharmacological agents on portal hypertension: a haemodynamic appraisal. (1985) (52)
- Left ventricular hypertrophy in rats with biliary cirrhosis (2003) (52)
- Liver Stiffness 1 Year After Transplantation Predicts Clinical Outcomes in Patients With Recurrent Hepatitis C (2014) (51)
- Effects of continued NO inhibition on portal hypertensive syndrome after portal vein stenosis in rat. (1994) (50)
- The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique (2015) (50)
- Postprandial effects of dark chocolate on portal hypertension in patients with cirrhosis: results of a phase 2, double-blind, randomized controlled trial. (2012) (50)
- Oral administration of clonidine in patients with alcoholic cirrhosis. Hemodynamic and liver function effects. (1992) (50)
- Effects of splenic artery occlusion on portal pressure in patients with cirrhosis and portal hypertension (2006) (49)
- Pharmacologic management of portal hypertension. (2014) (49)
- The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery. (2019) (49)
- Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats. (2008) (49)
- Reduction of gastric hyperemia by glypressin and vasopressin administration in cirrhotic patients with portal hypertensive gastropathy (1994) (49)
- New cellular and molecular targets for the treatment of portal hypertension (2015) (48)
- Acute Variceal Bleeding (2012) (48)
- Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. (2020) (48)
- Portal hypertension in acute liver failure. (1992) (48)
- Effects of carbon dioxide vs helium pneumoperitoneum on hepatic blood flow (1998) (48)
- Effects of propranolol on arterial oxygenation and oxygen transport to tissues in patients with cirrhosis. (1990) (47)
- Systematic review with meta‐analysis: portal vein recanalisation and transjugular intrahepatic portosystemic shunt for portal vein thrombosis (2018) (47)
- Effects of acute normovolemic anemia on gastric mucosal blood flow in rats: role of nitric oxide. (1992) (47)
- Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: an individual patient based meta-analysis of two controlled trials. (2014) (47)
- Salvage transjugular intrahepatic portosystemic shunt: is it really life-saving? (2001) (47)
- Antiangiogenic and antifibrogenic activity of pigment epithelium-derived factor (PEDF) in bile duct-ligated portal hypertensive rats (2014) (47)
- Utility of Color Doppler Ultrasonography Predicting TIPS Dysfunction (2005) (46)
- Noninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosis (1995) (46)
- Timing Affects Measurement of Portal Pressure Gradient After Placement of Transjugular Intrahepatic Portosystemic Shunts in Patients With Portal Hypertension. (2017) (46)
- Reduction of portal pressure by isosorbide-5-mononitrate in patients with cirrhosis (1989) (45)
- Role of spontaneous portal-systemic shunting in hyperinsulinism of cirrhosis. (1984) (45)
- Self-Expandable Metal Stents in the Treatment of Acute Esophageal Variceal Bleeding (2011) (44)
- Disruption of negative feedback loop between vasohibin‐1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats (2014) (44)
- Acute delirium as a manifestation of obstructive sleep apnea syndrome. (1998) (44)
- Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case‐control study (2013) (44)
- Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension. (1992) (43)
- Effects of isosorbide-5-mononitrate on variceal pressure and systemic and splanchnic haemodynamics in patients with cirrhosis. (1996) (43)
- CO2 wedged hepatic venography in the evaluation of portal hypertension (2000) (43)
- NCX-1000, a Nitric Oxide–Releasing Derivative of UDCA, Does Not Decrease Portal Pressure in Patients With Cirrhosis: Results of a Randomized, Double-Blind, Dose-Escalating Study (2010) (43)
- Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. (2020) (43)
- The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. (2018) (42)
- Transjugular local thrombolysis with/without TIPS in patients with acute non-cirrhotic, non-malignant portal vein thrombosis. (2017) (42)
- Hypercoagulability in patients with chronic noncirrhotic portal vein thrombosis. (2012) (42)
- Identification and functional characterization of the hepatic stellate cell CD38 cell surface molecule. (2007) (42)
- Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies (2017) (42)
- Total effective vascular compliance in patients with cirrhosis. Effects of propranolol. (2002) (42)
- Evidence against a role for NADPH oxidase modulating hepatic vascular tone in cirrhosis. (2007) (41)
- Evaluation of regional hepatic perfusion (RHP) by contrast-enhanced ultrasound in patients with cirrhosis. (2011) (41)
- The relevance of portal pressure and other risk factors in acute gastro‐oesophageal variceal bleeding (2004) (41)
- Characterization and Proteome of Circulating Extracellular Vesicles as Potential Biomarkers for NASH (2020) (41)
- Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats. (2011) (41)
- Metabolic Characterization of Advanced Liver Fibrosis in HCV Patients as Studied by Serum 1H-NMR Spectroscopy (2016) (40)
- Vasopressin/nitroglycerin infusion vs. esophageal tamponade in the treatment of acute variceal bleeding: A randomized controlled trial (1990) (39)
- Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats. (2012) (39)
- Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. (2021) (39)
- Metformin reduces hepatic resistance and portal pressure in cirrhotic rats. (2015) (39)
- Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd‐Chiari syndrome (2006) (39)
- Terutroban, a TP‐receptor antagonist, reduces portal pressure in cirrhotic rats (2013) (39)
- Mitochondria‐targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats (2017) (37)
- Effects of metoclopramide and domperidone on azygos venous blood flow in patients with cirrhosis and portal hypertension (1986) (37)
- Gastric microcirculatory changes of Portal‐hypertensive rats can be attenuated by long‐term Estrogen‐progestagen treatment (1994) (37)
- Increased blood hemoglobin attenuates splanchnic vasodilation in portal-hypertensive rats by nitric oxide inactivation. (1996) (37)
- Effects of increasing blood hemoglobin levels on systemic hemodynamics of acutely anemic cirrhotic patients. (1998) (36)
- Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. (2002) (36)
- Portal Hypertension in the 21st Century (2012) (36)
- Randomized controlled trial of sclerotherapy versus somatostatin infusion in the prevention of early rebleeding following acute variceal hemorrhage in patients with cirrhosis. Variceal Bleeding Study Group. (1998) (35)
- Modulation of autophagy for the treatment of liver diseases (2014) (34)
- Portal Hypertension Secondary to Myelofibrosis: A Study of Three Cases (2005) (34)
- Sonographic diagnosis and hemodynamic correlation in veno‐occlusive disease of the liver (1993) (34)
- Emricasan Ameliorates Portal Hypertension and Liver Fibrosis in Cirrhotic Rats Through a Hepatocyte‐Mediated Paracrine Mechanism (2019) (33)
- Down-regulation of genes related to the adrenergic system may contribute to splanchnic vasodilation in rat portal hypertension. (2008) (33)
- Use of noninvasive markers of portal hypertension and timing of screening endoscopy for gastroesophageal varices in patients with chronic liver disease (2013) (33)
- Resemblance of the human liver sinusoid in a fluidic device with biomedical and pharmaceutical applications (2018) (32)
- The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of portal hypertension in rats (2008) (32)
- Effects of ritanserin, a selective and specific S2‐serotonergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long‐term bile duct ligation (1993) (32)
- Predictions from a hard liver. (2006) (32)
- Effects of warm ischemia and reperfusion on the liver microcirculatory phenotype of rats: underlying mechanisms and pharmacological therapy (2016) (32)
- Measurement of hepatic vein pressure gradient in children with chronic liver diseases. (2010) (31)
- Efficacy of activated recombinant factor VII (rFVIIa; NovoSeven®) in cirrhotic patients with upper gastrointestinal bleeding: a randomised placebo-controlled double-blind multicenter trial (2003) (31)
- Hepatic, splanchnic and systemic haemodynamic abnormalities in portal hypertension. (1992) (31)
- Influence of beta‐2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis (2006) (31)
- LP13 : Effect of long term viral suppression with sofosbuvir + ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertension (2015) (31)
- Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension (2019) (30)
- Hyperglucagonemia and hyperkinetic circulation after portocaval shunt in the rat. (1987) (30)
- Limitations of laser-Doppler velocimetry and reflectance spectrophotometry in estimating gastric mucosal blood flow. (1992) (30)
- Interaction between NO and COX pathways modulating hepatic endothelial cells from control and cirrhotic rats (2012) (30)
- Bhathal PS, Grossman HJ. Reduction of the increased portal vascular resistance of the isolated perfused cirrhotic rat liver by vasodilators (J Hepatol 1985; 1: 325–337) (2004) (30)
- Isosorbide-5-mononitrate in the treatment of pulmonary hypertension associated with portal hypertension. (1999) (30)
- Value of transient elastography measured with fibroscan in predicting the outcome of hepatic resection for hepatocellular carcinoma. (2015) (30)
- Nuclear deformation mediates liver cell mechanosensing in cirrhosis (2020) (29)
- Developments and controversies in the management of oesophageal and gastric varices (2010) (29)
- Measurement of hepatic blood flow, hepatic extraction and intrinsic clearance of indocyanine green in patients with cirrhosis. Comparison of a non-invasive pharmacokinetic method with measurements using hepatic vein catheterization (1991) (29)
- Cardiovascular Risk Factors and Systemic Endothelial Function in Patients With Cirrhosis (2013) (29)
- Impaired function of pancreatic islets from rats with portal hypertension resulting from cirrhosis and partial portal vein ligation (1994) (29)
- Metabolomics Discloses Potential Biomarkers for the Noninvasive Diagnosis of Idiopathic Portal Hypertension (2013) (29)
- Insulin resistance in patients with cirrhosis and portal hypertension. (2012) (29)
- Development of analogues: successes and failures. (1998) (29)
- Simvastatin Attenuates Liver Injury in Rodents with Biliary Cirrhosis Submitted to Hemorrhage/Resuscitation (2017) (29)
- Effects of the V1a vasopressin agonist F‐180 on portal hypertension‐related bleeding in portal hypertensive rats (2003) (28)
- Patients whose first episode of bleeding occurs while taking a β-blocker have high long-term risks of rebleeding and death. (2012) (28)
- Potential role of antioxidants in the treatment of portal hypertension. (2007) (28)
- Effects of somatostatin in patients with portal hypertension. (1988) (28)
- Anemia Worsens Hyperdynamic Circulation of Patients with Cirrhosis and Portal Hypertension (1997) (27)
- Hemostatic effect of activated recombinant factor VII (rFVIIa) in liver disease: studies in an in vitro model. (2003) (26)
- Aging Influences Hepatic Microvascular Biology and Liver Fibrosis in Advanced Chronic Liver Disease (2019) (26)
- Transjugular portal vein recanalization with creation of intrahepatic portosystemic shunt (PVR-TIPS) in patients with chronic non-cirrhotic, non-malignant portal vein thrombosis (2017) (26)
- Long‐term effects of distal splenorenal shunt on hepatic hemodynamics and liver function in patients with cirrhosis: Importance of reversal of portal blood flow (1992) (26)
- 106 EFFICACY AND SAFETY OF ANTICOAGULATION IN PATIENTS WITH CIRRHOSIS AND PORTAL VEIN THROMBOSIS (2012) (25)
- The extent of the collateral circulation influences the postprandial increase in portal pressure in patients with cirrhosis (2006) (25)
- Hemodynamic effects of alpha-adrenergic blockade with prazosin in cirrhotic patients with portal hypertension. (1994) (25)
- Carvedilol: the β-blocker of choice for portal hypertension? (2013) (25)
- New approaches in the pharmacologic treatment of portal hypertension. (1993) (25)
- Increased CD11b neutrophil expression in Budd–Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera (2004) (25)
- Diagnostic performance of Baveno IV criteria in cirrhotic patients with upper gastrointestinal bleeding: analysis of the F7 liver-1288 study population. (2010) (25)
- Pharmacologic prevention of variceal bleeding and rebleeding (2018) (25)
- [785] RECOMBINANT FACTOR VIIA (RFVIIA) FOR ACTIVE VARICEAL BLEEDING IN PATIENTS WITH ADVANCED CIRRHOSIS: A MULTI-CENTRE RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL (2007) (25)
- Pharmacological versus endoscopic therapy in the prevention of variceal hemorrhage: And the winner is… (2009) (24)
- Impaired mesenteric leukocyte recruitment in experimental portal hypertension in the rat (1999) (24)
- The coagulopathy of cirrhosis: Myth or reality? (2005) (24)
- Management of gastrointestinal bleeding in patients with cirrhosis of the liver. (2004) (24)
- Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis (2021) (24)
- Assessment of Hepatic Vascular Network Connectivity with Automated Graph Analysis of Dynamic Contrast-enhanced US to Evaluate Portal Hypertension in Patients with Cirrhosis: A Pilot Study. (2015) (24)
- β‐Blockade with propranolol and hepatic artery blood flow in patients with cirrhosis (1989) (23)
- Atrophy of mesenteric sympathetic innervation may contribute to splanchnic vasodilation in rat portal hypertension (2010) (23)
- Prolonging survival in patients with cirrhosis: old drugs with new indications. (2010) (23)
- Lymphocyte beta 2-adrenoceptors and plasma catecholamines in patients with cirrhosis. (1992) (23)
- Effects of propranolol on gastric microcirculation and acid secretion in portal hypertensive rats (1990) (23)
- Efficacy and safety of simtuzumab for the treatment of nonalcoholic steatohepatitis with bridging fibrosis or cirrhosis: results of two phase 2b, dose-ranging, randomized, placebo-controlled trials (2017) (22)
- Prognostic Significance of Controlled Attenuation Parameter in Patients With Compensated Advanced Chronic Liver Disease (2018) (22)
- Portal hypertension: pre-primary and primary prophylaxis of variceal bleeding. (2008) (22)
- Gas Exchange and Pulmonary Vascular Reactivity in Patients with Liver Cirrhosis1–4 (2015) (22)
- Variceal Bleeding: Pharmacological Therapy (2005) (22)
- Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study (2015) (22)
- A novel form of the human manganese superoxide dismutase protects rat and human livers undergoing ischaemia and reperfusion injury. (2014) (22)
- Acute propranolol administration effectively decreases portal pressure in patients with TIPS dysfunction (2003) (21)
- Esophageal varices: Stage-dependent treatment algorithm. (2016) (21)
- Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis. (2013) (21)
- Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. (2021) (21)
- A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients (2017) (20)
- Role of gap junctions modulating hepatic vascular tone in cirrhosis (2014) (20)
- Impact of prior portosystemic shunt procedures on outcome of liver transplantation. (2005) (20)
- Effects of molsidomine, a long acting venous dilator, on portal hypertension. A hemodynamic study in patients with cirrhosis. (1991) (20)
- Combinations of simple baseline variables accurately predict sustained virological response in patients with recurrent hepatitis C after liver transplantation (2013) (20)
- Future treatments of cirrhosis (2014) (20)
- A Prognostic Strategy Based on Stage of Cirrhosis and HVPG to Improve Risk Stratification After Variceal Bleeding (2020) (20)
- Gastric mucosal resistance to acute injury in experimental portal hypertension (2001) (20)
- Circulatory response to volume expansion and transjugular intrahepatic portosystemic shunt in refractory ascites: Relationship with diastolic dysfunction. (2015) (20)
- Circulatory effects of graded diversion of portal blood flow to the systemic circulation in rats: Role of nitric oxide (1997) (20)
- [Portal hypertension: recommendations for evaluation and treatment: consensus document sponsored by the Spanish Association for the Study of the Liver (AEEH) and the Biomedical Research Network Center for Liver and Digestive Diseases(CIBERehd)]. (2012) (20)
- Emerging therapies for portal hypertension in cirrhosis (2016) (20)
- Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. (2022) (20)
- Nicardipine increases hepatic blood flow and the hepatic clearance of indocyanine green in patients with cirrhosis. (1994) (20)
- Statins in cirrhosis—Ready for prime time (2017) (19)
- Towards the non-invasive diagnosis of cirrhosis: the nuts-cirrhosis connection. (2009) (19)
- Balloon Tamponade and Esophageal Stenting for Esophageal Variceal Bleeding in Cirrhosis: A Systematic Review and Meta-analysis (2019) (19)
- Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis (2012) (19)
- 25 Value of hvpg predicting 5-day treatment failure in acute variceal bleeding. Comparison with clinical variables (2006) (19)
- Laparoscopic cholecystectomy in cirrhotic patients (1995) (19)
- Ischemia/reperfusion injury in the aged liver: The importance of the sinusoidal endothelium in developing therapeutic strategies for the elderly. (2019) (18)
- Nitric oxide-mediated beta 2-adrenoceptor relaxation is impaired in mesenteric veins from portal-hypertensive rats. (1996) (18)
- Overlooked subclinical portal hypertension in non-cirrhotic NAFLD: Is it real and how to measure it? (2021) (18)
- Aetiology of cirrhosis of the liver has an impact on survival predicted by the Model of End‐stage Liver Disease score (2009) (18)
- Nitric Oxide and Portal Hypertension (2002) (18)
- Use of piretanide, a new loop diuretic, in cirrhosis with ascites: relationship between the diuretic response and the plasma aldosterone level. (1980) (18)
- Hyperglucagonism and glucagon resistance in cirrhosis. Paradoxical effect of propranolol on plasma glucagon levels. (1988) (18)
- Therapy: Statins and liver disease: from concern to 'wonder' drugs? (2015) (17)
- Reliability of the estimation of total hepatic blood flow by Doppler ultrasound in patients with cirrhotic portal hypertension. (2013) (17)
- Effects of ritanserin, a selective and specific S2‐serotonergic antagonist, on portal pressure and splanchnic hemodynamics in portal hypertensive rats (1991) (17)
- Assessment of portal hypertension in humans. (2001) (17)
- Characterization of platelet and soluble-porcine P-selectin (CD62P). (2003) (17)
- Patients With Signs of Advanced Liver Disease and Clinically Significant Portal Hypertension Do Not Necessarily Have Cirrhosis. (2019) (17)
- Session 5: Treatment of the Acute Bleeding Episode (2007) (16)
- A Machine Learning Approach to Liver Histological Evaluation Predicts Clinically Significant Portal Hypertension in NASH Cirrhosis (2021) (16)
- Randomised clinical trial: the safety and efficacy of long‐acting octreotide in patients with portal hypertension (2012) (16)
- HCV Eradication Results in Reduction of Hepatic Venous Pressure Gradient 48 Weeks after End of Treatment; Final Results of the Study of Sofosbuvir plus Ribavirin in Patients with Cirrhosis and Portal Hypertension (2016) (16)
- A prospective observational study on tolerance and satisfaction to hepatic haemodynamic procedures (2015) (16)
- Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. (2021) (16)
- Anemia increases gastric blood flow in noncirrhotic and cirrhotic patients. (1995) (16)
- A Nutraceutical Rich in Docosahexaenoic Acid Improves Portal Hypertension in a Preclinical Model of Advanced Chronic Liver Disease (2019) (15)
- Medical Treatment of Portal Hypertension (1998) (15)
- Role and therapeutic potential of vascular stem/progenitor cells in pathological neovascularisation during chronic portal hypertension (2016) (15)
- Stenosis of the suprahepatic inferior vena cava as a complication of transjugular intrahepatic portosystemic shunt in Budd‐Chiari patients (2001) (15)
- O167 ADDITION OF SIMVASTATIN TO STANDARD TREATMENT IMPROVES SURVIVAL AFTER VARICEAL BLEEDING IN PATIENTS WITH CIRRHOSIS. A DOUBLE-BLIND RANDOMIZED TRIAL (NCT01095185) (2014) (15)
- Human amniotic stem cells improve hepatic microvascular dysfunction and portal hypertension in cirrhotic rats (2020) (15)
- 23 Nadolol+Isosorbide-5-mononitrate (NAD+ISMN) vs NAD+ISMN + endoscopic band ligation in the prevention of rebleeding in patients with cirrhosis. Preliminary results of a multicenter RCT (2006) (15)
- Pathophysiology and a Rational Basis of Therapy (2015) (14)
- Long term follow‐up of 100 patients with portal hypertension treated by a modified splenorenal shunt (1986) (14)
- ESOPHAGEAL VARICEAL BLEEDING CAUSED BY HYPOPLASIA OF THE PORTAL VEIN IN A PATIENT WITH THE KLIPPEL-TRENAUNAY SYNDROME (1998) (14)
- Increased plasma volume in two models of portal hypertension in the rat: cirrhosis of the liver and partial portal vein ligation. (1987) (14)
- The Splanchnic Circulation in Cirrhosis (2007) (14)
- A la carte or menu fixe: Improving pharmacologic therapy of portal hypertension (2002) (14)
- Duodenal variceal bleeding treated with a transjugular intrahepatic portosystemic shunt. (1995) (13)
- Constitutive NOS isoforms account for gastric mucosal NO overproduction in uremic rats. (1997) (13)
- Anatomical differences in responsiveness to vasoconstrictors in the mesenteric veins from normal and portal hypertensive rats (1996) (13)
- Splanchnic and Hepatic Metabolism of Somatostatin: A Study in Cirrhotic Patients with a Portacaval Shunt (2007) (13)
- Pathophysiology of portal hypertension in HCV-related cirrhosis. Putative role of assessment of portal pressure gradient in Peginterferon-treated patients. (2005) (13)
- Small diameter TIPS should lead to safely expanding the use of TIPS. (2020) (13)
- New Rat Model of Advanced NASH Mimicking Pathophysiological Features and Transcriptomic Signature of The Human Disease (2019) (13)
- Metabolomics as a diagnostic tool for idiopathic non‐cirrhotic portal hypertension (2016) (13)
- Exudative Ascites in the Course of Acute Type B Hepatitis (2007) (13)
- 992 AN EARLY DECISION FOR PTFE-TIPS IMPROVES SURVIVAL IN HIGH RISK CIRRHOTIC PATIENTS ADMITTED WITH AN ACUTE VARICEAL BLEEDING. A MULTICENTER RCT (2008) (12)
- Hyperkinetic circulation and decreased sensitivity to vasoconstrictors following portacaval shunt in the rat. Effects of chronic nitric oxide inhibition. (1999) (12)
- A Specialized, Nurse-Run Titration Clinic: A Feasible Option for Optimizing β-Blockade in Non–Clinical Trial Patients (2010) (12)
- Prognosis of acute variceal bleeding: Is being on beta‐blockers an aggravating factor? A short‐term survival analysis (2015) (12)
- Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. (2021) (12)
- Textbook of Clinical Gastroenterology and Hepatology: Hawkey/Textbook of Clinical Gastroenterology and Hepatology (2012) (12)
- Medical management of variceal bleeding in patients with cirrhosis. (2004) (12)
- Mechanical pumping of portal blood to the liver: hemodynamic effects of a new experimental treatment for portal hypertension. (1996) (12)
- Increased plasma endothelin concentration in atherosclerotic renovascular hypertension. (1995) (12)
- [The applicability and diagnostic effectiveness of transjugular liver biopsy]. (1996) (12)
- [Budd-Chiari syndrome associated with chronic myeloproliferative syndromes: analysis of 6 cases]. (1996) (12)
- Non-invasive tests for clinically significant portal hypertension after HCV cure. (2022) (11)
- A la carte or menu fixe: Improving pharmacologic therapy of portal hypertension. (2002) (11)
- Macitentan Improves Risk Categorization for Liver Transplant Mortality in Patients With Portopulmonary Hypertension: A PORTICO Study Post Hoc Analysis (2020) (11)
- Prevalence , and Clinical Significance of Abnormal ematologic Indices in Compensated Cirrhosis (11)
- Selective arterial embolization for life threatening hemobilia after transjugular intrahepatic portosystemic shunt placement. (2001) (11)
- Prevention of Variceal Rebleeding: Endoscopes, Drugs, and More (2000) (11)
- Portal hypertension. (1989) (11)
- [Effects of percutaneous intrahepatic portosystemic shunt on splanchnic and systemic hemodynamics in patients with portal hypertension]. (1997) (11)
- Changes in Fibrosis, but not the Nafld Activity Score (NAS), are Associated with Disease Progression in Patients with Nonalcoholic Steatohepatitis (NASH) and Advanced Fibrosis (2017) (11)
- Primary prophylaxis of esophageal variceal bleeding in cirrhosis. (2008) (10)
- Feasibility and safety of pancreatic islet transplantation in the liver by portal vein catheterization using the transjugular route. (2006) (10)
- The management of portal hypertension. (2005) (10)
- Clinical Manifestations and Management of Bleeding Episodes in Cirrhotics (2008) (10)
- Decreasing hepatic vascular tone by liver-specific NO donors: wishful thinking or a promising reality? (2003) (10)
- Large‐conductance calcium‐activated potassium channels modulate vascular tone in experimental cirrhosis (2008) (10)
- Oxidative Stress in Chronic Liver Disease and Portal Hypertension: Potential of DHA as Nutraceutical (2020) (10)
- Effects of end‐to‐side portacaval shunt and distal splenorenal shunt on systemic and pulmonary haemodynamics in patients with cirrhosis (1999) (10)
- Soft technique, hard end-points. (2011) (10)
- Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis (2019) (10)
- Early periportal sinusoidal fibrosis is an accurate marker of accelerated HCV recurrence after liver transplantation. (2014) (10)
- Propranolol plus molsidomine vs propranolol alone in the treatment of portal hypertension in patients with cirrhosis. (1996) (10)
- Carvedilol for preventing recurrent variceal bleeding: Waiting for convincing evidence (2013) (10)
- Abnormal Liver Function Test in Patients Infected with Coronavirus (SARS-CoV-2): A Retrospective Single-Center Study from Spain (2021) (9)
- Small diameter shunts should lead to safe expansion of the use of TIPS (9)
- Effect of poorly absorbable antibiotics on hepatic venous pressure gradient in cirrhosis: A systematic review and meta-analysis. (2020) (9)
- Hemodynamic response to propranolol in patients with recurrent hepatitis C virus–related cirrhosis after liver transplantation: A case‐control study (2013) (9)
- An early decission for PTFE-TIPS improves survival in high risk cirrhotic patients admitted with an acute variceal bleeding. A multicenter RCT (2008) (9)
- Measurement of the azygos venous blood flow as an index of variceal blood flow in cirrhosis with portal hypertension (1982) (9)
- Efficacy of somatostatin and vasopressin in the control of acute variceal hemorrhage (1985) (9)
- Monitoring of HVPG during pharmacological therapy: Evidence in favor of the prognostic value of a 20% reduction (2004) (9)
- Effect of transjugular intrahepatic portosystemic shunt (TIPS) on renal function and vasoactive systems in hepatorenal syndrome (SHR) (1998) (8)
- Medical treatment of portal hypertension. (2000) (8)
- Beta‐blockers in 2016: Still the safest and most useful drugs for portal hypertension? (2016) (8)
- CLINICAL EVENTS AFTER TIPS : CORRELATION WITH HEMODYNAMIC FINDINGS. AUTHORS' REPLY (1998) (8)
- Impact of hepatic encephalopathy on liver transplant waiting list mortality in regions with different transplantation rates (2018) (8)
- The HVPG-response to pharmacological treatment of portal hypertension predicts prognosis and the risk of developing complications of cirrhosis (2002) (8)
- Effects of propranolol on venous compliance in conscious rats with pre-hepatic portal hypertension. (2006) (8)
- Indocyanine-green: infusion rate and reactions. (1989) (8)
- Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications (2020) (7)
- The sixth Carlos E. Rubio Memorial Lecture. Prevention and treatment of variceal hemorrhage. (2000) (7)
- Rolling review: the treatment of major complications of cirrhosis. (1994) (7)
- Spironolactone (Sp) decreases portal pressure in patients with compensated cirrhosis (1991) (7)
- An apology for beta blockers. (2014) (7)
- Other clinical studyNoninvasive measurement of femoral blood flow and portal pressure response to propranolol in patients with cirrhosis (1995) (7)
- Transcriptomic Profiling of the Liver Sinusoidal Endothelium during Cirrhosis Reveals Stage-Specific Secretory Signature (2021) (7)
- The resistance of the cirrhotic liver: a new target for the treatment of portal hypertension. 1985. (2004) (7)
- Therapy in liver diseases : the pathophysiological basis of therapy (1997) (7)
- Clinical events following TIPS: Correlation with hemodynamic findings (1995) (7)
- 5 Pharmacological prevention of variceal bleeding. New developments (1997) (6)
- Is treatment with nadolol effective against the growth of small esophageal varices in patients with cirrhosis? (2005) (6)
- Systemic, splanchnic and humoral changes after orthotopic liver transplantation (OLT) in cirrhosis (1991) (6)
- Portal Hypertension and Cirrhosis: From Evolving Concepts to Better Therapies (2020) (6)
- Effects of propranolol on gastric mucosal blood flow and acid secretion in portal hypertensive rats (1989) (6)
- Correspondence. Is the Concept of “Exudative” Ascites Useful? (1984) (6)
- Pharmacological Agents and Portal Hypertension (1991) (6)
- Calculating Hepatic Venous Pressure Gradient: Feel Free to Stay Free. (2016) (6)
- 130 Pharmacological reduction of portal pressure and long term risk of first variceal bleeding in patients with cirrhosis (2003) (6)
- Late Breaking Abstract - Efficacy and safety of macitentan in portopulmonary hypertension: the PORTICO trial (2018) (6)
- [236] ACUTE HVPG RESPONSE TO I. V. PROPRANOLOL AND RISK OF PORTAL HYPERTENSION RELATED BLEEDING (2007) (6)
- Diagnostic Methods for Cirrhosis and Portal Hypertension (2018) (6)
- A reduction in the hepatic venous pressure gradient (HVPG) prevents clinical outcomes in compensated and decompensated cirrhosis: a meta-analysis (2017) (6)
- LBO-01-Multicenter, double-blind, placebo-controlled, randomized trial of emricasan in subjects with NASH cirrhosis and severe portal hypertension (2019) (6)
- 19 DARK CHOCOLATE ATTENUATES THE POST-PRANDIAL INCREASE IN HVPG IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION (2010) (6)
- Improved survival with nonselective beta blockers (2008) (6)
- Editorial: increased cardiac output in cirrhosis – non‐invasive assessment of regional blood flow by magnetic resonance angiography (2016) (6)
- Effects of spontaneous bacterial peritonitis (SBP) on systemic and splanchnic hemodynamics in patients with cirrhosis (2001) (5)
- Portal Hypertension in Cirrhosis (2018) (5)
- Novel approaches to treat portal hypertension (2002) (5)
- P‐selectin mediates leukocyte rolling in concanavalin‐A‐induced hepatitis (2005) (5)
- Pathophysiology of variceal bleeding (2004) (5)
- Ascites and renal failure in primary liver cell carcinoma. (1975) (5)
- Endogenous nitric oxide is involved in hemodynamics disturbances in portal hypertensive (PH) rats (1991) (5)
- Regarding “liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution” (2014) (5)
- Use of statins after liver transplantation is associated with improved survival: results of a nationwide study (2022) (5)
- Pharmacological prevention of variceal bleeding. New developments. (1997) (5)
- 100 TRANSLOCATION OF BACTERIAL DNA IS ASSOCIATED WITH WORSENING OF THE HYPERKINETIC SYSTEMIC CIRCULATION AND OF INTRA-HEPATIC ENDOTHELIAL DYSFUNCTION IN PATIENTS WITH CIRRHOTIC AND ASCITES (2009) (5)
- EUS-guided intrahepatic portosystemic shunt: A real alternative to transjugular intrahepatic portalsystemic shunt? (2017) (5)
- Preventing decompensation of cirrhosis with clinically significant portal hypertension and without high-risk varices: a new indication for non-selective beta-blockers (NSBB) (2017) (5)
- Lack of effect of pentoxifylline on portal pressure and hepatic haemodynamics in cirrhosis (1990) (5)
- Esophageal Stents for Acute Variceal Bleeding: Expanding the Possibilities (2018) (5)
- Obstruction of the Portal Vein (2008) (5)
- [Neonatal aortic thrombosis]. (1980) (4)
- Lack of hemodynamic response to long-acting octreotide (Sandostatin LAR) in patients with cirrhosis (2001) (4)
- Propranolol plus placebo versus propranolol plus isosorbide‐5‐mononitrate in the prevention of a first variceal bleed: a doubleblind RCT (2003) (4)
- O017A : Non-invasive tools and risk of varices and clinically significant portal hypertension in compensated cirrhosis: the “anticipate” study (2015) (4)
- 209 CARDIOMYOPATHY IN PATIENTS WITH CIRRHOSIS. FREQUENCY, CHARACTERISTICS AND RELATIONSHIP WITH CIRCULATORY DYSFUNCTION AND PROGNOSIS (2009) (4)
- Normalization of portal pressure (PP) following end-to-side portacaval shunt (PCS) worsens systemic hemodynamic abnormalities in cirrhosis (1991) (4)
- Measurement of Azygos Blood Flow (1991) (4)
- P-selectin mediates leukocyte rolling in concanavalin-A-induced hepatitis. (2005) (4)
- [Vasoactive drugs for the treatment of bleeding esophageal varices]. (2004) (4)
- Letter: improve survival! Place early pre-emptive TIPSS in high-risk variceal bleeders. (2020) (4)
- Transvenous liver biopsies in marrow transplant recipients. (1995) (4)
- Clinical Features and Natural History of Variceal Hemorrhage (2005) (4)
- Reversal of portal blood flow after distal splenorenal shunt (DSRS). Relationship to hepatic encephalopathy and impaired liver function (1989) (4)
- 422 IDIOPATHIC PORTAL HYPERTENSION: IMPACT OF HEPATIC VEIN CATHETERIZATION AND TRANSIENT ELASTOGRAPHY ON ITS DIAGNOSIS (2010) (4)
- Hepatic Venous Pressure Measurement and Other Diagnostic Hepatic Hemodynamic Techniques (2018) (4)
- Isosorbide 5-mononitrate (ISMN) increases plasma renin activity (PRA) and aldosterone (ALD) and impairs renal function in cirrhosis with ascites (1991) (4)
- Cirrhotic livers exhibit a hyperesponse to methoxamine. Role of nitric oxide and eicosanoids (2001) (4)
- 179 Oxidative stress reduces nitric oxide biodisponibility and may contribute to endothelial dysfunction of cirrhotic livers (2006) (4)
- Letter: nonselective beta‐blockers, endoscopic therapy and portal vein thrombosis in cirrhosis (2019) (4)
- Simvastatin ammeliorates the increased hepatic vascular tone in patients with cirrhosis (2003) (3)
- [87] EFFICACY OF ANTIVIRAL THERAPY ON DISEASE PROGRESSION IN HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: A RANDOMIZED CONTROLLED STUDY (2007) (3)
- Splanchnic vasodilation and renal vasoconstriction: A key to the hepatorenal syndrome? (1990) (3)
- Non-invasive measurement of HVPG using graph analysis of dynamic contrast-enhanced ultrasound: the CLEVER study (2018) (3)
- 107 EFFECTS OF SIMVASTATIN ADMINISTRATION ON LIVER MICROVASCULAR DYSFUNCTION INDUCED BY LPS (2011) (3)
- Cardiac structure and function in experimental intra-hepatic portalhypertension (2000) (3)
- HVPG Measurements as a Surrogate of Clinical Events in Cirrhosis: Experience from Clinical Trials (2019) (3)
- [Renal insufficiency caused by diuretics in liver cirrhosis with ascites]. (1973) (3)
- Somatostatin is less effective decreasing portal pressure during acute variceal bleeding than in stable conditions (1998) (3)
- [118] EXTRACELLULAR SUPEROXIDE DISMUTASE GENE TRANSFER REDUCES PORTAL PRESSURE AND IMPROVES INTRAHEPATIC ENDOTHELIAL DYSFUNCTION IN CIRRHOTIC RAT LIVERS BY DIMINISHING SUPEROXIDE AND INCREASING NITRIC OXIDE BIOAVAILABILITY (2007) (3)
- Pathophysiology of variceal bleeding in cirrhotics (2007) (3)
- Pathogenesis of Bleeding in Portal Hypertension (1998) (3)
- Editorial: improving in‐hospital management of decompensated cirrhosis by a ‘care bundle’ – hope, frustration, and lessons to learn (2017) (3)
- Effects of molsidomine. A long-acting venous dilator, on hepatic haemodynamics in patients with cirrhosis and portal hypertension (1989) (3)
- Clinical gastroenterology and hepatology (2005) (3)
- Intracellular and exchangeable potassium in cirrhosis (1981) (3)
- [Spontaneous ascites compensation in liver cirrhosis]. (1974) (3)
- Carvedilol (Carv) vs propranolol (Prop) in the long-term treatment ofportal hypertension (PH) (2000) (3)
- LETTERS TO THE EDITOR: TRANSVENOUS LIVER BIOPSIES IN MARROW TRANSPLANT RECIPIENTS (1995) (3)
- Portal-systemic shunting (PSS) influences hemodynamic abnormalities in bile duct ligated (BDL) rats (1991) (3)
- [83] TREATMENT OF BUDD CHIARI SYNDROME WITH TIPS. LONG-TERM RESULTS IN 124 PATIENTS AND EVALUATION OF PROGNOSTIC FACTORS (2007) (3)
- An update on the use of low-dose maintenance cyclosporine A therapy after renal transplantation. (1988) (3)
- Pathophysiology of portal hypertension and variceal bleeding (2009) (3)
- Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis (2022) (3)
- Hepatitis C virus RNA in patients with anti-HCV on hemodialysis. Relationship to transaminase levels. (1994) (3)
- [Somatostatin and its analogs in the treatment of gastrointestinal and liver diseases]. (1996) (3)
- Corrigendum to 'Baveno VII - Renewing consensus in portal hypertension' [J Hepatol (2022) 959-974]. (2022) (2)
- CLINICAL-LIVER, PANCREAS, AND BILIARY TRACT (2007) (2)
- Session 6 ‒ Treatment of the Acute Bleeding Episode (2008) (2)
- Propranolol in the prophylaxis of oesophageal variceal haemorrhage in patients with cirrhosis: A double-blind, multicenter controlled trial (1990) (2)
- PERSPECTIVES IN CLINICAL HEPATOLOGY Somatostatin and Analogues in Portal Hypertension (2002) (2)
- [218] BACTERIAL TRANSLOCATION INDUCES PROINFLAMMATORY CYTOKINES AND WORSENS SYSTEMIC HEMODYNAMICS IN CIRRHOTIC PATIENTS WITH ASCITES (2007) (2)
- Impact of modest weight reduction on liver histology, portal pressure, and clinical events in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (2017) (2)
- Stem cells as a new therapeutic strategy for portal hypertension and cirrhosis (2018) (2)
- Favorable effects of propranolol in patients with malfunctioning porto-caval or distal spleno-renal shunts (1989) (2)
- Rivaroxaban Reduces Portal Hypertension in Cirrhotic Rats by Deactivating Hepatic Stellate Cells and Reducing Intrahepatic Microthrombosis (2016) (2)
- Erratum: Noninvasive Prediction of Clinically Significant Portal Hypertension and Esophageal Varices in Patients With Compensated Liver Cirrhosis (2012) (2)
- Endoscopic measurement of variceal pressure (VP) in patients with cirrhosis. Correlation with the niec index (NI) and with the risk of variceal hemorrhage (1990) (2)
- The association of isosorbide-5-mononitrate enhances the reduction in portal pressure caused by propranolol in patients with cirrhosis (1990) (2)
- Evaluation of the portal hypertensive patient. (1989) (2)
- Diagnosis and evaluation of portal hypertension. (1988) (2)
- Statins in Portal Hypertension (2010) (2)
- [Functional component of portal hypertension]. (2004) (2)
- Natural History and Management of Esophagogastric Varices in Chronic Non-Cirrhotic Non-Tumoral Portal Vein Thrombosis (2016) (2)
- Comparative effects of the novel vasotocin analogue F-180 vs. vasopressin and terlipressin on systemic and splanchnic isolated vessels from portal hypertensive rats (2001) (2)
- Circadian variation of portal pressure in patients with cirrhosis. Relationship with variceal bleeding (1990) (2)
- Editorial: use of beta‐blockers and of band ligation in preventing first and recurrent variceal bleeding—“real life” vs evidence‐based decisions (2018) (2)
- Portal Vein Thrombosis in Patients with Cirrhosis. Incidence and Factors Associated with Its Development (2016) (2)
- 83 Transient elastography to evaluate the severity of hepatitis C recurrence after liver transplantation (2006) (2)
- [Triamterene in the treatment of liver cirrhosis with ascites]. (1972) (2)
- [Budd-Chiari syndrome]. (2000) (2)
- Sequential Functions of CPEB 1 and CPEB 4 Regulate Pathologic Expression of VEGF and Angiogenesis in Chronic Liver Disease (2015) (2)
- 147 HEPATIC ENCEPHALOPATHY IS AN INDEPENDENT RISK FACTOR FOR MORTALITY IN PATIENTS AWAITING LIVER TRANSPLANTATION (2013) (2)
- Royal Free Hospital‐estimated glomerular filtration rate for prognostic stratification of first acute kidney injury in cirrhosis (2020) (2)
- Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis (2021) (2)
- 4 Inhibition of VEGF receptor-2 (VEGFR-2) signaling prevents portal-systemic collateral (PSC) vessel formation in rats with portal hypertension (PH) (2004) (2)
- Comprar Textbook Of Clinical Gastroenterology And Hepatology 2nd Ed. | C. J. Hawkey | 9781405191821 | Wiley (2012) (2)
- Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)? (2021) (2)
- Stratified efficacy of first -line therapy to prevent first variceal bleeding according to previous decompensation of cirrhosis. A competing-risk meta-analyses of individual participant data (2022) (2)
- Intracellular and exchangeable potassium in cirrhosis. Evidence against the occurrence of potassium depletion in cirrhosis with ascites. (1981) (1)
- Pharmacological treatment of portal hypertension. (2001) (1)
- Hepatic encephalopathy is not a contraindication to pre-emptive TIPS in high-risk patients with cirrhosis with variceal bleeding (2022) (1)
- Incidence and factors predictive of recurrent thrombosis in patients with non-cirrhotic portal vein thrombosis. (2022) (1)
- LIVER NAD ( P ) H oxidase modulates angiogenesis and the development of portosystemic collaterals and splanchnic hyperaemia in portal hypertensive rats (2007) (1)
- 119 THE TRANSCRIPTION FACTOR KLF2 MEDIATES HEPATIC ENDOTHELIAL PROTECTION CONFERRED BY STATINS (2012) (1)
- An integrated MELD model including serum sodium, and age improves the prediction of early mortality in patients with cirrhosis (2007) (1)
- O39 LONG TERM OUTCOME OF MILD HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION: A LARGE PROSPECTIVE STUDY (2014) (1)
- FRI-439-Factor V and VIII may predict the risk of recurrent splanchnic thrombosis in patients with non-cirrhotic chronic portal vein thrombosis of local and idiopathic etiology not receiving anticoagulation (2019) (1)
- 762 TRANSIENT ELASTOGRAPHY (TE) IS MORE EFFECTIVE FOR THE IDENTIFICATION OF HCV PATIENTS WITH ADVANCED (F3-F4) RATHER THAN SIGNIFICANT (F2-F4) LIVER FIBROSIS (2008) (1)
- [Churg-Strauss syndrome: 8 cases in the last 10 years]. (1989) (1)
- O074 : A metabolomic study of serum from patients with cirrhosis identifies 2 metabolites that accurately predict the acute HVPG response to β-blocker therapy (2015) (1)
- Pulmonary arterial hypertension: an unusual cause of portal hypertension. (2012) (1)
- Effects of propranolol (Prop) and placebo (Pla) on oesophageal variceal pressure (OVP) in cirrhosis (1990) (1)
- Non-invasive measurement of HVPG using graph analysis based on dynamic contrast-enhanced ultrasound with ESAOTE MyLab: The CLEVER Study (2018) (1)
- Controlled attenuation parameter as an additional tool for the non-invasive prediction of first clinical decompensation in compensated advanced chronic liver disease (2017) (1)
- Bone morphogenetic protein receptor 2 in patients with idiopathic portal hypertension (2012) (1)
- Factors Predicting Survival In Patients With `Non-High-Risk' Acute Variceal Bleeding Receiving Nsbb And/Or Ebl To Prevent Re-Bleeding (2019) (1)
- Muscle abnormalities in cirrhosis: Calling for more strength in evaluation and prevention. (2019) (1)
- Long-term impact of HCV eradication after all-oral therapy in patients with clinical significant portal hypertension (2018) (1)
- Bacterial infections in cirrhotic patients with transjugular intrahepatic portosystemic shunt (2002) (1)
- Comparison of the effcts of propranolol (Prop) and placebo (Pla) on variceal pressure (VP) and hepatic venous pressure gradient (HVPG) in cirrhosis (1991) (1)
- Blood volume restitution during a portal hypertension-related bleedingin rats (2000) (1)
- Possibilities of manipulating nitric oxide biosynthesis in the treatment of portal hypertension: statins (2004) (1)
- Propranolol effectively decreases portal pressure in patients with tips dysfunction (2001) (1)
- 256 ONE MONTH CAFETERIA DIET INDUCES NAFLD AND LIVER SINUSOIDAL ENDOTHELIAL DYSFUNCTION IN RATS (2008) (1)
- Lymphocyte beta-2 adrenoceptors (LAR-B2), plasma catecholamines and haemodynamic response to propranolol (PROP) in patients with cirrhosis and portal hypertension. (1989) (1)
- Hyperglucagonism reduces the pressor response to angiotensin and vasopressin in portal hypertension (1990) (1)
- Prevention of Recurrent Bleeding from Esophageal Varices (2017) (1)
- Different effects of protein and carbohydrate meals on splanchnic hemodynamics and portal pressure in patients with cirrhosis (1988) (1)
- 563 A NOVEL RECOMBINANT FORM OF THE HUMAN MANGANESE SUPEROXIDE DISMUTASE PROTECTS RAT LIVER GRAFTS PROCURED FOR TRANSPLANTATION (2013) (1)
- Drug Therapy in Primary and Secondary Prevention of Variceal Hemorrhage in Portal Hypertension (1995) (1)
- What else we need (2004) (1)
- G10 : Mitochondrial-targeted antioxidant mitoquinone reduces portal hypertension in CCL4-cirrhotic rats by decreasing intrahepatic resistance (2015) (1)
- Prediction of fibrosis improvement in patients with advanced fibrosis due to NASH using a machine learning approach: Unravelling the placebo response (2018) (1)
- 504 EFFECTS OF THE COMBINED ADMINISTRATION OF SORAFENIB PLUS PROPRANOLOL ON PORTAL HYPERTENSION IN CIRRHOTIC RATS (2010) (1)
- Correlation between the Hepatic Venous Pressure Gradient and Alpha-Smooth Muscle Actin (SMA) Expression in Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (2016) (1)
- Reply to: Does the dose and type of NSBBs really matter? (2017) (1)
- Reply (2020) (1)
- 13C-methacetin breath test is a highly accurate non-invasive point of care test for detecting CSPH in patients with NASH (2018) (1)
- 260 SUCCESSFUL THERAPY WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN CAUSES A SUSTAINED DECREASE IN PORTAL PRESSURE IN PATIENTS WITH CHRONIC HEPATITIS C-RELATED CIRRHOSIS (2010) (1)
- 55 HEMODYNAMIC EFFECTS AND SAFETY OF ONE-MONTH SIMVASTATIN TREATMENT IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION. A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED MULTICENTER TRIAL (2008) (1)
- 551 OPTIMAL TIMING OF ENDOSCOPY IS ASSOCIATED WITH LOWER 42-DAY MORTALITY IN VARICEAL BLEEDING (2019) (1)
- 94 FUNCTIONAL ANALYSIS OF HEPATIC GENE EXPRESSION PROFILING FROM PATIENTS WITH ALCOHOLIC HEPATITIS REVEALS NEW TARGETS FOR THERAPY (2009) (1)
- Is it tea time for portal hypertension? (2014) (1)
- The combined chronic administratton of propranolol (Prop) and isosorbide-5-mononitrate (Is-5-Mn) achieve greater beneficial effects than either drug alone (1989) (1)
- O148 KLF2 UP-REGULATION DECREASES HEPATIC FIBROSIS AND AMELIORATES ENDOTHELIAL DYSFUNCTION IN CIRRHOTIC RATS (2014) (1)
- PS-022-Optimal timing of endoscopy is associated with lower 42-day mortality in variceal bleeding (2019) (1)
- 590 ASSESSMENT OF SYSTEMIC ENDOTHELIAL FUNCTION IN PATIENTS WITH CIRRHOSIS: COMPARISON BETWEEN PERIPHERAL ARTERIAL TONOMETRY (PAT) AND BRACHIAL ARTERY VASODILATATION BY ULTRASOUND (BAUS) (2011) (1)
- FIB-4 improves LSM-based prediction of complications in overweight or obese patients with compensated advanced chronic liver disease. (2021) (1)
- FRI-113-Matrix stiffness modulates the phenotype of hepatic cells in cirrhosis and modifies the sinusoidal effects of statins (2019) (1)
- Sarcopenia predicts mortality after transjugular intrahepatic portosystemic shunt creation in patients with refractory ascites (2020) (1)
- Sarcopenia correlates with mortality in cirrhotic patients who undergo transjugular intrahepatic portosystemic shunt creation for refractory ascites (2020) (1)
- Prevention of variceal rebleeding (2003) (1)
- P518 HEPATIC VENOUS PRESSURE GRADIENT, ASA CLASS AND TYPE OF SURGERY ARE PROGNOSTIC FACTORS OF EXTRA-HEPATIC SURGERY IN PATIENTS WITH CIRRHOSIS: A MULTI-CENTER PROSPECTIVE OBSERVATIONAL STUDY (2014) (1)
- 287 Predicting survival in portal hypertension: HVPG, child-pugh, or MELD? (2003) (0)
- O17 IMPACT OF ANTICOAGULANT THERAPY ON UPPER GASTROINTESTINAL BLEEDING (UGI) IN PATIENTS WITH LIVER CIRRHOSIS. RESULTS FROM A RETROSPECTIVE MULTICENTRIC CASE–CONTROL STUDY (2014) (0)
- Novel in vivo tracing of the hepatocyte origin of extracellular vesicles in mice with experimental liver disease (2020) (0)
- BASIC AND TRANSLATIONAL — LIVER Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension (0)
- Hemodynamic effects of an acute increase in intra-abdominal pressure (IAP) in patients with cirrhosis (1991) (0)
- FRI-110-A nutraceutical supplement rich in docosahexaenoic acid improves portal hypertension in a pre-clinical model of chronic liver disease (2019) (0)
- [190] INHIBITION OF ADRENERGIC TRANSMISSION MAY CONTRIBUTE TO SPLANCHNIC VASODILATION IN PORTAL HYPERTENSION (2007) (0)
- Reply (2016) (0)
- Pre-emptive (early) transjugular intrahepatic porto-systemic shunt in the treatment of high-risk acute variceal bleeding. An individual patient data meta-analysis (2020) (0)
- How to evaluate portal hypertension Is HVPG measurement a relevant gold standard for portal hypertension assessment ? (2012) (0)
- S1918 A Hemodynamic Response to Treatment With Non-Selective Beta-Blockers Protects Against Worsening of Thrombocytopenia in Cirrhosis (2010) (0)
- [The "Liver" Study Group: portal hypertension]. (1988) (0)
- Reply (2014) (0)
- 451 CLINICAL, HISTOLOGICAL AND HEMODINAMIC OUTCOMES IN HCV-INFECTED LIVER TRANSPLANT RECIPIENTS TREATED WITH PEGILATED INTERFERON PLUS RIBAVIRIN (2009) (0)
- Authors' response (2010) (0)
- New Drugs in the Treatment of Portal Hypertension (2010) (0)
- Characterization of gastric mucosal damage induced by aspirin in portal hypertensive rats (1998) (0)
- An Unusual Cause of Portal Hypertension (2012) (0)
- Corrigendum to: "Impaired endothelial autophagy promotes liver fibrosis by aggravating the oxidative stress response during acute liver injury" [J Hepatol (2019) 458-469]. (2020) (0)
- Bacterial deoxyribonucleic is frequent in blood samples of patients with compensated cirrhosis and obesity and is associated with lack of decrease of portal pressure after an intensive lifestyle intervention (2017) (0)
- Reply (2017) (0)
- PostersPoster Session – Friday, April 20, 201202c. Cirrhosis and ITS Complications: Bleeding661 USE OF EARLY-TIPS FOR HIGH-RISK VARICEAL BLEEDING. RESULTS OF A POST-RCT SURVEILLANCE STUDY (2012) (0)
- SAT-079-Respiratory infection in patients with cirrhosis and acute variceal bleeding on antibiotic prophylaxis: A multicenter observational study of 2138 patients (2019) (0)
- 508 INSULIN RESISTANCE AND DIABETES DO NOT INFLUENCE HEPATIC AND SYSTEMIC HEMODYNAMICS OR THE HVPG RESPONSE TO PROPRANOLOL IN PATIENTS WITH CIRRHOSIS (2010) (0)
- In Memoriam: Roberto J. Groszmann, MD (1939-2021). (2021) (0)
- Chair: General Session 4. General Hepatology (Cirrhosis, transplantation and tumour) EASL LiverTree™. (2016) (0)
- EASL recognition awardee 2013: Dr. Andrew Kenneth Burroughs. (2013) (0)
- Emerging Therapeutic Targets for Portal Hypertension (2023) (0)
- Reply (2018) (0)
- Simvastatin ameliorates the sinusoidal microcirculatory phenotype, fibrosis and portal hypertension in aged cirrhotic rats (2017) (0)
- Accurate prediction of clinical disease progression in patients with advanced fibrosis due to NASH using a Bayesian machine learning approach (2018) (0)
- [Endotoxin and hepatic cirrhosis]. (1979) (0)
- Hemodynamic effects of albumin administration in spontaneous bacterial peritonitis (2002) (0)
- Budd-Chiari Syndrome 13 (2011) (0)
- 276 PRELIMINARY EFFICACY AND SAFETY OF REPEATED ORAL DOSES OF NCX-1000 FOR THE TREATMENT OF PORTAL HYPERTENSION. A DOUBLE-BLIND, PROOF OF CONCEPT, DOSE ESCALATING STUDY (2008) (0)
- The Treatment and Prevention of Variceal Bleeding (2011) (0)
- Hepatic Encephalopathy is an Independent Risk Factor for Transplant-Free Survival in Patients Awaiting Liver Transplantation (2016) (0)
- Quantifying the benefit of non-selective beta-blockers in the prevention of hepatic decompensation: a Bayesian re-analysis of the PREDESCI trial. (2023) (0)
- FRI-324-Introducing a new pre-clinical model of advanced NASH that mimics the main pathophysiologic characteristics and transcriptomic signature of the human disease (2019) (0)
- Endoscopic Assessment of Portal Hypertension Including Variceal Pressure Measurements (2005) (0)
- Angiogenesis in liver disease q (2009) (0)
- Correspondence (0)
- Early-tips should be performed in high-risk cirrhotic patients despite the presence of hepatic encephalopathy at admission (2020) (0)
- PNPLA3 Variants Confer an Increased Risk of Advanced Fibrosis Due to Non-Alcoholic Steatohepatitis (2016) (0)
- Genome-Wide Association Study of Clinically Significant Portal Hypertension in Patients with Nonalcoholic Steatohepatitis and Advanced Fibrosis (2016) (0)
- Increased vascular resistance to portal blood flow is the primary factor promoting portal hypertension in carbon tetrachloride cirrhotic rats (1985) (0)
- Clinical and genetic factors associated with regression of fibrosis in ACLD after etiological therapy (2022) (0)
- Arterial resistance (1990) (0)
- ACUTE VOLUME EXPANSION AND TIPS FAILS TO INDUCE CHANGES OF IMPENDING HEART FAILURE IN PATIENTS WITH REFRACTORY ASCITES (2011) (0)
- [198] ROLE OF GTP CYCLOHYDROLASE AND TETRAHYDROBIOPTERIN IN THE REGULATION OF HEPATIC VASCULAR TONE (2007) (0)
- Reply (to LTE HEP-19-0411). (2019) (0)
- Letter: PCSK9 inhibitor for liver transplant patients during the post‐statin era? Authors' reply (2022) (0)
- Serum bile acids are markedly elevated in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH) (2018) (0)
- Table of contents (2016) (0)
- Emerging future therapies for portal hypertension (2008) (0)
- Portal hypertension, news and views year 2016 (2016) (0)
- 148 A RANDOMIZED TRIAL OF THE SAFETY AND HEPATIC HEMODYNAMIC EFFECTS OF INTRAVENOUS CONIVAPTAN IN EUVOLEMIC OR HYPERVOLEMIC CIRRHOTIC PATIENTS (2011) (0)
- Chapter 45 – Portal and Splenic Vein Thrombosis (2012) (0)
- Effects of Acute Normovolemic Gastric Mucosal Blood Flow in Nitric Oxide (1992) (0)
- 20 PPARα ACTIVATION REDUCES PORTAL PRESSURE AND AMELIORATES ENDOTHELIAL DYSFUNCTION IN CIRRHOSIS (2010) (0)
- Reply (2019) (0)
- n etwork connectivity with automated graph analysis of Dynamic contrast-enhanced U s to evaluate Portal hypertension in Patients with cirrhosis: A Pilot (2015) (0)
- Clinically significant portal hypertension in chronic liver disease: Always cirrhosis? (2018) (0)
- Reply (2017) (0)
- 120 UNVEILING A NEW MECHANISM OF REGULATION OF ANGIOGENESIS IN PORTAL HYPERTENSION THROUGH TRANSLATIONAL CONTROL BY THE CPEB FAMILY OF PROTEINS (2012) (0)
- Reduction of vascular compliance by propranolol influences the portal pressure response to pharmacological therapy (1998) (0)
- P517 EFFECTS OF SAPROPTERIN ON PORTAL AND SYSTEMIC HEMODYNAMICS IN PATIENTS WITH CIRRHOSIS AND PORTAL HYPERTENSION: A BICENTRIC DOUBLE-BLIND PLACEBO CONTROLLED STUDY (2014) (0)
- Functional Gastrointestinal Disease (2012) (0)
- Reply (2016) (0)
- 207 PERIPORTAL SINUSOIDAL FIBROSIS IS AN EARLY MARKER OF PORTAL HYPERTENSION AND SIGNIFICANT FIBROSIS IN HEPATITIS C RECURRENCE AFTER LIVER TRANSPLANTATION (2012) (0)
- 591 TERUTROBAN, A TXA2/PGH2 RECEPTOR ANTAGONIST, REDUCES PORTAL PRESSURE, AMELIORATES INTRAHEPATIC VASCULAR RESISTANCE AND INCREASES NITRIC OXIDE BIOAVAILABILITY IN CIRRHOTIC RAT LIVERS (2012) (0)
- Noninvasive tests in the post–liver transplantation setting (2007) (0)
- 606 LIVER ENDOTHELIAL DYSFUNCTION AFTER LPS ADMINISTRATION: A ROLE FOR INDUCIBLE-NITRIC OXIDE SYNTHASE (2011) (0)
- Reply to: "Pre-emptive TIPS for acute variceal bleeding in acute-on-chronic liver failure: Is there enough evidence for a routine recommendation?": pTIPS for variceal bleeding in ACLF patients: when and why? (2020) (0)
- Identification of Cell Apoptosis by Terminal Deoxynucleotidyl Transferase – Mediated Deoxyuridine Triphosphate Nick-End Labeling (0)
- Portal hypertension from molecular biology to clinical practice (2011) (0)
- Diagnostic accuracy of liver and spleen stiffness measurement for portal hypertension using bidimensional shear weave elastography (2015) (0)
- PS-017-Long-term impact of sustained virological response on systemic and pulmonary hemodynamics in HCV-cirrhotic patients with portal hypertension (2019) (0)
- Ultrasound parameters in the prediction of clinically significant portal hypertension (CS-PHT) in compensated cirrhosis (2000) (0)
- 435 PORTAL HYPERTENSION AND HEPATIC VENOUS- VENOUS COMMUNICATIONS IN PATIENTS WITH BILIARY ATRESIA (2009) (0)
- Preemptive TIPS for the treatment of bleeding from gastric fundal varices: results of a randomized-controlled trial (2023) (0)
- Simvastatin Impedes the Endotoxin-Induced Aggravation of Hepatic Microvascular Dysfunction in Two Animal Models of Liver Cirrhosis (2016) (0)
- Ritanserin decreases portal pressure (PP) in portal vein ligated and cirrhotic rats (1991) (0)
- The Incidence of Rethrombosis in Patients with Non-Cirrhotic, Non-Tumoral Chronic Portal Vein Thrombosis – A Prospective Observational Study (2016) (0)
- 742 SYMPATHETIC NERVE REGRESSION AS A POSSIBLE FACTOR CONTRIBUTING TO SUPERIOR MESENTERIC ARTERY VASODILATION IN EXPERIMENTAL PORTAL HYPERTENSION (2009) (0)
- Increased variability and loss of accurracy of hepatic hemodynamic measurements under deep sedation in patients with portal hypertension: 3AP4-3 (2011) (0)
- New Targets in Therapy: Statins, Antioxidants and Antiangiogenic Strategies (2016) (0)
- 193 RELIABILITY OF THE ESTIMATION OF HEPATIC BLOOD FLOW (HBF) BY DOPPLER ULTRASOUND IN PATIENTS WITH CIRRHOTIC PORTAL HYPERTENSION: COMPARISON WITH HBF BY INDOCYANINE GREEN (2013) (0)
- Exploring metabolic space of advanced chronic liver disease regression (2022) (0)
- Standardisation of Portal Pressure Gradients Measurements after Tips Does it Matter (2016) (0)
- 39 BONE MORPHOGENETIC PROTEINS (BMP) AND BMP SIGNALLING ARE SIGNIFICANTLY INCREASED IN EXPERIMENTAL MODELS OF CIRRHOSIS AND PORTAL HYPERTENSION (2009) (0)
- Role of angiogenesis in portal hypertension (2008) (0)
- 187 ANTIVIRAL THERAPY IN RECURRENT HEPATITIS C: ADVANCED DONOR AGE AND FEMALE RECIPIENT GENDER IDENTIFY NON RESPONDERS AT HIGHER RISK OF GRAFT LOSS (2012) (0)
- Effects of isosorbide-5-mononitrate (Is-5-Mn) on hepatic haemodynamics in cirrhotic rats (1990) (0)
- Mineralocorticoid escape in compensated cirrhotics with portal hypertension. Relationship with natriuretic and antinatriuretic systems (1990) (0)
- 1876-P: Impact of Diabetes on Liver Disease Progression in Patients with Advanced Fibrosis Due to Nonalcoholic Steatohepatitis (NASH) (2019) (0)
- Non-invasive pulsed-doppler evaluation of the patency and blood flow in distal spleno-renal shunts. Comparisons with direct measurements at catheterization (1989) (0)
- Cancer Antigen 125 in Serumand AsciticFluidof PatientswithLiverDiseases (1991) (0)
- Physiology of the Splanchnic and Hepatic Circulations (2011) (0)
- EASL Recognition Award Recipient 2015: Prof. Roberto de Franchis. (2015) (0)
- Reply to: ''Effect of albumin on survival in septic cirrhotic patients other than spontaneous bacterial peritonitis. The question remains open'' (2013) (0)
- 757 3-DAY ADMINISTRATION OF A HIGH FAT DIET INDUCES HEPATIC STEATOSIS AND LIVER ENDOTHELIAL INSULIN RESISTANCE (2009) (0)
- [Hyperpotassemia as cause of death in hepatic cirrhosis]. (1974) (0)
- 944 PATIENTS WITH CIRRHOSIS WHO FAILED PRIMARY PROPHYLAXIS WITH NON-SELECTIVE BETA-BLOCKERS HAVE AN INCREASED RISK OF REBLEEDING DESPITE ADDING ENDOSCOPIC VARICEAL LIGATION (2011) (0)
- Reply (2011) (0)
- Shunt surgery and beta-blockers. (1994) (0)
- A hypercoagulable state does not play a major role in the development of portal vein thrombosis in patients with cirrhosis (2020) (0)
- The Challenge of Drug-Induced Liver Injury (DILI) / Challenges and Management of Liver Cirrhosis: The Challenge of Drug-Induced Liver Injury (DILI) Falk Workshop, Freiburg, October 2014 Challenges and Management of Liver Cirrhosis Falk Symposium 195, Freiburg, October 2014 (2015) (0)
- Reply: (2011) (0)
- PP27 – A novel recombinant form of the human manganese superoxide dismutase protects liver grafts procured for transplantation (2013) (0)
- [Terlipressin in the treatment of portal hypertension]. (1998) (0)
- Early ALT elevation is highly predictive of severe fibrosis and portal hypertension one year after liver transplantation in HCV-infected patients (2003) (0)
- 621 IMPROVING RISK PREDICTION IN ACUTE VARICEAL BLEEDING WITH OBJECTIVE VARIABLES: THE ROLE OF MELD (2013) (0)
- Reply: (2017) (0)
- 98. Portal hypertension (2012) (0)
- Andrew Kenneth Burroughs (1953–2014) (2014) (0)
- Reply: (2002) (0)
- 173 RIGTH ATRIAL PRESSURE IS NOT ADEQUATE TO CALCULATE THE PORTAL PRESSURE GRADIENT IN CIRRHOSIS. A CLINICAL-HEMODYNAMIC CORRELATION STUDY (2010) (0)
- Autophagy regulates endothelial dysfunction and hepatic fibrosis development (2017) (0)
- Haemodynamic Assessment of Portal Hypertension (2008) (0)
- Portal Hypertension: Extrahepatic Mechanisms (2011) (0)
- Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies (2017) (0)
- Appropriate Use of Artificial Nutrition and Hydration (2006) (0)
- Carvedilol as best beta-blocker for secondary prophylaxis of variceal bleeding: Are we there, or not yet? (2022) (0)
- Role and Modulation of Nitric Oxide in the Cirrhotic Liver (2014) (0)
- Consensus Statements: Session 2—Impact of Etiological and Anti-fibrotic Therapy (2016) (0)
- Insulin and glucagon secretion in isolated pancreatic islets from rats with CCL4-induced cirrhosis (1989) (0)
- Somatostatin (SMT) reduces urinary prostaglandin (PG) excretion and impairs renal function in cirrhosis with ascites (1991) (0)
- To the Editor (0)
- A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients (2017) (0)
- Effective portal-pressure gradient reduction after small diameter TIPS. (2021) (0)
- Pathophysiology of Bleeding and Hepatorenal Syndrome (1998) (0)
- Prognostic value of hepatic clearance of indocyanine green (ICG) in cirrhotic patients who have bled from oesophageal varices (1989) (0)
- Nicardipine increases hepatic blood flow and the hepatic clearance of ICG in patients with cirrhosis (1990) (0)
- 677 Hepatic gene expression analysis in acute alcoholic hepatitis identifies nadph oxidase and GRO-α as potential therapeutical targets (2006) (0)
- Utility of duplex sonography predicting TIPS dysfunction (2003) (0)
- 門脈圧亢進症および静脈瘤出血--未解決の問題。米国肝臓学会および欧州肝臓学会共同主催のシングルトピックカンファレンスの概要 (2008) (0)
- Tips in Budd Chiari Syndrome: Long-term results in 124 patients and evaluation of prognostic factors: A multicentre study (2007) (0)
- Portal Hypertension III. Proceedings of the Third Baveno International Concensus Workshop on Definitions, Methodology and Therapeutic Strategies R. de Franchis, editor; Blackwell Science Limited, Oxford, 2001, ISBN: 0-632-05918-4 (2001) (0)
- 531 EARLY IDENTIFICATION OF TWO PATTERNS OF HEPATITIS C RECURRENCE (RAPID AND SLOW PROGRESSORS) AFTER LIVER TRANSPLANTATION: A PROSPECTIVE LONG-TERM FOLLOW-UP STUDY (2011) (0)
- 523 HEMODYNAMIC EFFECTS OF TEZOSENTAN, A DUAL ENDOTHELIN RECEPTOR ANTAGONIST, IN PATIENTS WITH CIRRHOSIS (2010) (0)
- Molecular abnormalities in portal hypertension: diagnostic, prognostic and therapeutic implications (2012) (0)
- Clinical types anddrugtherapy ofrenal impairment incirrhosis (1975) (0)
- P0020 : Role of endothelial autophagy in liver Ischemia and Reperfusion injury (2015) (0)
- Transcatheter arterial embolization (TAE) for hepatocellular carcinoma (HCC): Beneficial effects on portal pressure (1991) (0)
- Liver stiffness predicts the development of portal hypertension related complications in advanced chronic liver disease (2018) (0)
- The splanchnic hyperemia of portal hypertension can be attenuated by increasing red blood cell volume. A nitric oxide related mechanism (1995) (0)
- EASL International Recognition Award Recipient 2016: Prof. Roberto J. Groszmann. (2016) (0)
- Role of Circulating Propionate in Portal Hypertension in Cirrhosis (2016) (0)
- Increased sinusoidal pressure impairs liver endothelial mechanosensing, uncovering novel biomarkers of portal hypertension (2023) (0)
- P460 A METABOLOMIC PROFILE INCLUDING 5 LIPIDIC METABOLITES CORRELATES WITH DIAGNOSIS OF IDIOPATHIC PORTAL HYPERTENSION (2014) (0)
- Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis (2011) (0)
- Reply: To PMID 23908019. (2014) (0)
- Treatment of variceal bleeding in patients with cirrhosis of the liver (2005) (0)
- Use of Vasoactive Drugs for Acute Variceal Bleeding (2014) (0)
- Annals for Hospitalists Inpatient Notes - Clinical Pearls—Hepatorenal Syndrome (2021) (0)
- Effect of rifaximin or norfloxacin on hepatic venous pressure gradient in patients with cirrhosis: a systematic review and meta-analysis (2020) (0)
- 210 SUSTAINED VIROLOGICAL RESPONSE WITH PEG-INTERFERON alfa-2a AND RIBAVIRIN DECREASES PORTAL PRESSURE GRADIENT AND PREVENTS CLINICAL DECOMPENSATION IN PATIENTS WITH CHRONIC HEPATITIS C RELATED CIRRHOSIS (2013) (0)
- Reply: To PMID 23058320. (2013) (0)
- Noninvasive point-of-care 13C-Methacetin Breath Test (MBT) predicts risk of clinical deterioration independently of currently used prognostic indicators in patients with decompensated NASH cirrhosis (2020) (0)
- Regulation of Hepatic Vascular Tone in Chronic Liver Disease (2016) (0)
- 178 COMPARISON OF ULTRASONOGRAPHIC EVALUATION OF LIVER SURFACE AND TRANSIENT ELASTOGRAPHY IN THE DIAGNOSIS OF CIRRHOSIS AND PORTAL HYPERTENSION (2009) (0)
- Subcutaneous adipose tissue is a predictor of survival in patients with hepatocellular carcinoma (2018) (0)
- 766 Early lobular necrosis and living donor liver transplantation are strong predictors of severe HCV recurrence after liver (2003) (0)
- The maintenance of increased glucagon levels preclude the effects of somatostatin on splanchnic haemodynamics in portal hypertensive rats (1989) (0)
- Whole exome sequencing identifies rare nonsense mutations enriched among patients with advanced fibrosis due to nonalcoholic steatohepatitis (2018) (0)
- Worsening of low-grade systemic inflammation heralds decompensation in patients with compensated cirrhosis (2022) (0)
- 576 EFFECTS OF ENOXAPARIN ADMINISTRATION ON CCl4 CIRRHOTIC RATS WITH PORTAL HYPERTENSION (2013) (0)
- From prognostic factors to personalized medicine. (2020) (0)
- Response to Talwalkar (2011) (0)
- Author's response: Terlipressin in the treatment of portal hypertension (1999) (0)
- Reply (2017) (0)
- Tips improves survival in Budd-Chiari Syndrome (BCS) (2000) (0)
- 198 RENIN-ANGIOTENSIN-ALDOSTERONE INHIBITORS FOR THE REDUCTION OF PORTAL PRESSURE: A META-ANALYSIS AND SYSTEMATIC REVIEW (2010) (0)
- Effects of propranolol on gastric microcirculation in cirrhotics with portal hypertensive gastropathy (1991) (0)
- PS-023-Factors predicting survival in patients with high-risk acute variceal bleeding treated with pre-emptive (Early)-TIPS (2019) (0)
- [Pharmacologic treatment of portal hypertension]. (1991) (0)
- Highlights on portal hypertension at the 2015 AASLD Meeting (2016) (0)
- [Intrahepatic percutaneous portasystemic shunt]. (1994) (0)
- elastography in clinically doubtful cirrhosis q (2010) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Jaime Bosch?
Jaime Bosch is affiliated with the following schools:
